Abstract
By primary prevention aimed at avoiding or averting environmental factors thought to promote disease in genetically at-risk individuals T1D would be eradicated ideally, but these factors have not been identified and may be ubiquitous. Since the early 1980s, secondary prevention, after the disease process has started, has been the focus of considerable attention and with many candidate agents, mainly immunosuppressive drugs have been trialled, usually after the onset of clinical diabetes. Prevention is however more applicable to early, preclinical disease rather than to recent onset clinical disease, when beta cell destruction is more advanced. Prevention of the infectious disease by exposing the immune system to the weakened or dead infectious agent has been a traditional vaccination method. Alternate method called “inverse vaccination” (the inhibition of immune response) arrests autoimmunity through manipulation of the innate and adaptive arms of the immune system. Inverse vaccination specifically reduces a pathological adaptive autoimmune response. Targeted reduction of unwanted antibody and T-cell responses to autoantigens is allowed by inverse vaccination, while leaving the remainder of the immune system intact. Varying degree of success in suppression of β-cell autoimmunity in NOD mice have been shown by current options for treatment of autoimmunity such as immunosuppressive drugs (e.g. cyclosporine) and anti T-cell antibodies (e.g. anti-CD3 antibodies). But the drawback with these methods is that it requires repeated administration and may lead to non-specific harmful effects such as interference with normal immune system functions. Whereas, antigen specific immunotherapy (ASI) uses inverse vaccination for a specific auto-antigen. The advantage with the ASI is selective inactivation of auto-reactive T cells without interference in normal immune function. Major examples of antigen specific immunotherapy agent at various stage of clinical trials are alum formulated glutamic acid decarboxylase and heat shock protein and peptide 277.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cernea, S., Dobreanu, M., Raz, I.: Prevention of type 1 diabetes: today and tomorrow. Diabetes Metab. Res. Rev. 26, 602–605 (2010)
Harrison, L.C.: The prospect of vaccination to prevent type 1 diabetes. Hum. Vaccin. 1, 143–150 (2005)
Ludvigsson, J.: The role of immunomodulation therapy in autoimmune diabetes. J. Diabetes Sci. Technol. 3, 320–330 (2009)
Appel, S.J., et al.: Latent autoimmune diabetes of adulthood (LADA): an often misdiagnosed type of diabetes mellitus. J. Am. Acad. Nurse Pract. 21, 156–159 (2009)
Hjorth, M. Immunological profile and aspects of immunotherapy in type 1 diabetes. Linköping University Medical dissertations, vol. 1161 (2010). liu.diva-portal.org/smash/get/diva2:279876/FULLTEXT01. Accessed 26 Aug 2012
Raz, I., Eldor, R., Naparstek, Y.: Immune modulation for prevention of type 1 diabetes mellitus. Trends Biotechnol. 23, 128–134 (2005)
Zhang, L., Eisenbarth, G.S.: Prediction and prevention of type 1 diabetes mellitus. J. Diabetes 3, 48–57 (2011)
Tian, J., Kaufman, D.L.: Antigen-based therapy for the treatment of type 1 diabetes. Diabetes 58, 1939–1946 (2009)
Boettler, T., von Herrath, M.: Type 1 diabetes vaccine development: animal models vs. humans. Hum. Vaccin. 7, 19–26 (2011)
Nicholas, D., Odumosu, O., Langridge, W.H.: Autoantigen based vaccines for type 1 diabetes. Discov. Med. 11, 293–301 (2011)
Steinman, L.: Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity. J. Intern. Med. 267, 441–451 (2010)
Petrovsky, N., Silva, D., Schatz, D.A.: Vaccine therapies for the prevention of type 1 diabetes mellitus. Paediatr. Drugs 5, 575–582 (2003)
Gupta, S.K.: Vaccines for type 1 diabetes in the late stage of clinical development. Indian J. Pharmacol. 43, 485 (2011)
Sanjeevi, C.B.: Type 1 diabetes research: Newer approaches and exciting developments. Int. J. Diabetes Dev Ctries 29, 49–51 (2009)
Faustman, D.L., et al.: Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One 7, e41756 (2012)
Clemente-Casares, X., Tsai, S., Huang, C., Santamaria, P.: Antigen-specific therapeutic approaches in type 1 diabetes. Cold Spring Harb. Perspect. Med. 2, a007773 (2012)
Zhang, Z.J., Davidson, L., Eisenbarth, G., Weiner, H.L.: Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. U. S. A. 88, 10252–10256 (1991)
Herold, K.C., et al.: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698 (2002)
Chatenoud, L., Thervet, E., Primo, J., Bach, J.F.: Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 91, 123–127 (1994)
Bour-Jordan, H., Bluestone, J.A.: B cell depletion: a novel therapy for autoimmune diabetes? J. Clin. Invest. 117, 3642–3645 (2007)
Pescovitz, M.D., et al.: Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361, 2143–2152 (2009)
Huppmann, M., Baumgarten, A., Ziegler, A.G., Bonifacio, E.: Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care 28, 1204–1206 (2005)
Fischer, B., Elias, D., Bretzel, R.G., Linn, T.: Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update. Expert Opin. Biol. Ther. 10, 265–272 (2010)
Rewers, M., Gottlieb, P.: Immunotherapy for the prevention and treatment of type 1 diabetes. Diabetes Care 32, 1769–1782 (2009)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Gupta, S.K. (2014). Vaccines for Type 1 Diabetes. In: Giese, M. (eds) Molecular Vaccines. Springer, Cham. https://doi.org/10.1007/978-3-319-00978-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-00978-0_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-00977-3
Online ISBN: 978-3-319-00978-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)